Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 16/20 | 0.53 |
| ▸ | F10 | P00742 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932736 | 0.84 | F2 (0.63) | F2F10 | |
| SCHEMBL6926155 | 0.80 | MEN1 (0.43) | MEN1KMT2AL3MBTL1ADORA2AADORA1 | |
| SCHEMBL6931900 | 0.69 | F2 (1.00) | F2F10 | |
| SCHEMBL6931431 | 0.69 | F2 (1.00) | F2F10 | |
| SCHEMBL8276486 | 0.68 | F2 (1.00) | F2F10 | |
| SCHEMBL6925582 | 0.67 | F2 (0.84) | F2F10 | |
| SCHEMBL6926191 | 0.67 | F2 (0.66) | F2F10 | |
| SCHEMBL6932678 | 0.66 | F2 (1.00) | F2F10MEN1KMT2A | |
| SCHEMBL6931474 | 0.66 | F2 (0.86) | F2F10MEN1KMT2A | |
| SCHEMBL6925359 | 0.65 | F2 (1.00) | F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | claimed |
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225131-A1 | Thrombin inhibitors | TFPI, SERPINC1, PLAT | F2 5/4885F10 27/4885MEN1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.